EXAGEN INC. (XGN) Reports the reporting period Financial Results
EXAGEN INC. (XGN) announced its financial results for the period ending the reporting period.
Key Financial Highlights:
Revenue: 675
Net Income: Not disclosed
EPS: Not disclosed
Cash and equivalents: 32220
3 %Operating expenses$14,181 $52,869 Loss from operations$(4,975)$(14,070)Net loss$(4,673)$(19,951)Adjusted EBITDA$(3,670)$(9,794)Cash, cash equivalents and restricted cash$32,420Trailing
month average selling price (ASP)$4412025 Highlights:
Supported the diagnosis and management of care for over 137,000 patients tested by AVISE CTD.
📋 EXAGEN INC. (XGN) - Financial Results
Filing Date: 2026-03-10
Accepted: 2026-03-10 08:03:45
Event Type: Financial Results
Event Details:
📊 Key Financial Metrics (Year-over-Year Comparison):
💼 Business Developments:
No business developments data available.
Structured Data: